Similarly, disease-free survival was found to be longer in patients with glioma with high expression of ADD2, CTC1, SRCIN1, RORA, VPS4A, and ULK2 than in those with low expression (Figures 5C–H). This evidence concerns the gene SRCIN1 and glioma.